HeartCare management and its honoured guests celebrate the listing in HKEX

Shanghai HeartCare Medical is an euro-interventional medical device manufacturer which focuses on reducing the mortality rate an dimproving the prognosis of stroke.

Since founding in 2016, the company has commercialised 7 products and has a total of 23 approved products and product can didates covering all major stroke subtypes in the neuro-interventional field, with ischemic stroke prevention product can didates to capture demand from the cardiac market.

HeartCare provides the first total solution for treatment of AIS in China and its product candidate of Rapamycin eluting balloon catheter is the world‘s First of its kind for treatment of intracranial stenosis.

The successful listing is a milestone of HeartCare development and we wish to develop and commercialize more and more quality products to benefit stroke patients around the world.

HeartCare Chairman Wang Guohui and local government official Wu Xiaohua strike the “Gong” at HKEX.